VRTX Vertex Pharmaceuticals Incorporated

154.76
-0.29  -0%
Previous Close 155.05
Open 155.29
Price To book 23.34
Market Cap 39017916166
Shares 252,118,869
Volume 1,048,487
Short Ratio 2.07
Av. Daily Volume 1,378,063

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data released July 18, 2017. ppFEV1 of 9.6 percentage points.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
Phase 2 trial initiation announced December 21, 2016. Data due by end of 2017.
CTP-656
Cystic fibrosis
Phase 3 data released March 28, 2017 - primary endpoint met. PDUFA date under priority review February 28, 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 3 data released March 28, 2017 - primary endpoint met. NDA filing due 3Q 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
Phase 3 data released November 7, 2016 met primary endpoint.
ORKAMBI
Two Copies of the F508del Mutation
Phase 3 data due 2H 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation

Latest News

  1. Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
  2. See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
  3. Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
  4. This Pharma Stock Is Up 111% and Investors Are Wondering What's Next
  5. Vertex Announces 10-Year, $500 Million Corporate Giving Commitment
  6. Vertex to Announce Third Quarter 2017 Financial Results on October 25
  7. Wall Street analysts expect gains of up to 64% on their favorite health-care stocks
  8. The 1 Stock You've Been Overlooking for Your Roth IRA
  9. Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day
  10. Bull of the Day: Vertex Pharmaceuticals (VRTX)
  11. Pres Trump believes he has the cure for Obamacare
  12. Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : October 10, 2017
  13. Amgen Label Expansion Application for Prolia Accepted by FDA
  14. 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
  15. Why the Earnings Streak Will Continue for Vertex Pharmaceuticals (VRTX)
  16. Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
  17. Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : October 9, 2017
  18. Alexion on the Street: Analyst Recommendations in October
  19. 3 Top-Ranked Big Biotech Stocks to Buy Now
  20. 3 Reasons To Like Vertex Pharma Shares